iRECIST: A clarification of tumour response assessment in the immunotherapy era

Charles Ferté¹, Aurélien Marabelle²

• ¹Early Drug Development Unit (DITEP), Gustave Roussy, Paris Saclay University, Villejuif, France; Head and neck cancer department, Gustave Roussy, Paris Saclay University, Villejuif, France; INSERM U1030, Gustave Roussy, Paris Saclay University, Villejuif, France.+1